ABION's ABN202 Shows Promise Against ADC-Resistant Tumors

ABION (ABN) reported positive findings for its drug ABN202 in a study focused on tumor resistance to antibody-drug conjugates (ADCs). The research indicates that ABN202 may effectively target and treat ADC-resistant tumors, demonstrating significant potential for enhancing cancer treatment options. With ADC therapies rapidly evolving, ABN202's efficacy could impact market strategies in oncology. Further details about dosing or trial sizes were not disclosed, leaving market reactions dependent on upcoming results.